Major Trends and Emerging Patterns in the Cancer Immunotherapy Drug Discovery Outsourcing Market: Strategic Partnerships Driving Cancer Immunotherapy Drug Discovery Outsourcing
Discover trends, market shifts, and competitive outlooks for the cancer immunotherapy drug discovery outsourcing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Key Milestones in the Cancer Immunotherapy Drug Discovery Outsourcing Market’s Growth Trajectory From 2025 To 2034?
The market for outsourcing the discovery of cancer immunotherapy drugs has witnessed a significant expansion in the past few years. The market, projected to be worth $1.5 billion in 2024, is expected to reach $1.68 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. Factors such as a rise in adverse drug reactions, heightened demand for extensive genomic testing, an escalating global prevalence of cancer, an increased necessity for targeted therapies, and a surge in clinical trials have contributed to the growth during the historical period.
Anticipated to see swift expansion over the forthcoming years, the market for outsourced discovery of cancer immunotherapy drugs is likely to reach a valuation of $2.57 billion by 2029, growing at a compounded annual rate of 11.3%. The market’s progression during the forecast period can be attributed to factors such as the growing significance of personalized medicine, the rise in diagnostic tests, heightened focus on individualized cancer treatment, increase in healthcare expenditure, and a surge in the incidence and awareness of cancer. Key trends for the forecast period include advancements in diagnostic technology, the rise of next-generation sequencing (NGS), incorporation of artificial intelligence (AI), emerging liquid biopsy technologies, development of point-of-care companion diagnostic devices, and innovative testing procedures.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Cancer Immunotherapy Drug Discovery Outsourcing Market?
The escalating expenses involved in research and development are predicted to fuel the expansion of the cancer immunotherapy drug discovery outsourcing market. These growing expenses are primarily attributed to the necessity for specialized expertise, high-cost equipment, and the inherent potential risks associated with innovation. By outsourcing drug discovery processes, smaller biotech companies and startups can benefit from the economies of scale offered by contract research organizations (CROs), allowing them to maximize their R&D budgets and distribute resources more effectively, thereby increasing cost-efficiency. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade association that represents the pharmaceutical industry in Europe, reported in June 2023 that the overall pharmaceutical R&D expenditure in Europe for the year 2022 reached $49,500 million (€44,500 million), marking a rise of nearly 6.45% from $46,500 million (€42,533 million) in 2021. Thus, the soaring costs of conducting in-house research and development are driving the growth of the cancer immunotherapy drug discovery outsourcing market.
Which Primary Segments of the Cancer Immunotherapy Drug Discovery Outsourcing Market Are Driving Growth and Industry Transformations?
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas
Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp
Which Regions Are Key Players in the Growth of the Cancer Immunotherapy Drug Discovery Outsourcing Market?
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Cancer Immunotherapy Drug Discovery Outsourcing Market?
Leading businesses in the cancer immunotherapy drug discovery outsourcing market are turning to strategic partnerships to aid in the production of cancer-fighting drugs and secure a competitive industry edge. Strategic partnerships are typically defined as a collaborative effort between two or more organizations, pooling their resources, skills, and hard work to accomplish shared aspirations or aims. For example, in February 2022, Japanese pharmaceutical company, Ono Pharmaceutical Co., Ltd., and the US biopharmaceutical firm, Bristol-Myers Squibb, entered into an outsourcing deal with Prime Research Institute for Medical Research, Inc., another Japanese research institute. The collaboration project is aimed at clinical research catering to stomach cancer patients treated with a combined regimen of Opdivo (nivolumab) and chemotherapy. This large-scale, inter-institutional research, sponsored by the industry, uses PRiME-R’s CyberOncology, a data input support system that simplifies the standardization, structure, administration, and merging of real-world data in regular cancer medical procedures. Evaluating the combination of Opdivo with chemotherapy for untreated advanced or recurring gastric cancer, this clinical study involves around 30 nationwide medical institutions aiming to enhance data input efficiency, improve data accuracy, and hasten the analysis process.
View the full report here:
What Parameters Are Used to Define the Cancer Immunotherapy Drug Discovery Outsourcing Market?
Cancer immunotherapy drug discovery outsourcing is a specialized service model in the pharmaceutical and biotech sectors. It entails delegating aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs) to speeds up innovation by leveraging external expertise and resources, letting pharmaceutical companies focus on core activities.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15528
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
